Background
Brian Rifkin
Is REACT (Renal Autologous Cell Therapy) the ...

This week, we will discuss the use of renal autologous cell therapy (REACT) in diabetic kidney disease.

Is REACT (Renal Autologous Cell Therapy) the “fifth pillar” in diabetic kidney disease?
Background
Brian Rifkin
2026 KDIGO Anemia Management Guidelines

This week, we will discuss 2026 KDIGO anemia management in patients with kidney disease

2026 KDIGO Anemia Management Guidelines
Background
Cristina Adriana Popa
To INFINITI and Beyond: SGLT2 Inhibitors in ...

This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.

To INFINITI and Beyond: SGLT2 Inhibitors in Kidney Transplant Patients
Background
Cristina Adriana Popa
POTCAST- K+ Pop and Arrhythmia Drop

This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.

POTCAST- K+ Pop and Arrhythmia Drop
Background
Brian Rifkin
A VALIANT effort to combat complement disorders ...

This week, we will discuss the VALIANT study, pegcetacoplan in C3G and IC MPGN.

A VALIANT effort to combat complement disorders with pegcetacoplan

cardiovascular

Can Canaglifozin Communicate Consistency with CANVAS?

Can Canaglifozin Communicate Consistency with CANVAS?

Were the EMPA-REG Renal results chance, or is this a class effect? Let's take a deep dive into CANVAS, published in the NEJM recently, which examined the cardiovascular safety of canaglifozin in type 2 diabetes.